| Authors | Burnham, SC. Rowe, CC. Baker, D. Bush, AI. Doecke, JD. Faux, NG. Laws, SM. Martins, RN. Maruff, P. Macaulay, SL. Rainey-Smith, S. Savage, G. Ames, D. Masters, CL. Wilson, W. Villemagne, VL. |
|---|---|
| Type | Journal Article (Original Research) |
| Journal | Neurology |
| PubMed ID | 27534714 |
| Year of Publication | 2016 |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/27534714 |
| DOI | http://dx.doi.org/10.1212/WNL.0000000000003094 |
| Abstract | OBJECTIVE: We assessed a blood-based signature, which previously demonstrated high accuracy at stratifying individuals with high or low neocortical β-amyloid burden (NAB), to determine whether it could also identify individuals at risk of progression to Alzheimer disease (AD) within 54 months. METHODS: We generated the blood-based signature for 585 healthy controls (HCs) and 74 participants with mild cognitive impairment (MCI) from the Australian Imaging, Biomarkers and Lifestyle Study who underwent clinical reclassification (blinded to biomarker findings) at 54-month follow-up. The individuals were split into estimated high and low NAB groups based on a cutoff of 1.5 standardized uptake value ratio. We assessed the predictive accuracy of the high and low NAB groupings based on progression to mild cognitive impairment or AD according to clinical reclassification at 54-month follow-up. RESULTS: Twelve percent of HCs with estimated high NAB progressed in comparison to 5% of HCs with estimated low NAB (odds ratio = 2.4). Forty percent of the participants with MCI who had estimated high NAB progressed in comparison to 5% of the participants with MCI who had estimated low NAB (odds ratio = 12.3). These ratios are in line with those reported for Pittsburgh compound B-PET results. Individuals with estimated high NAB had faster rates of memory decline than those with estimated low NAB. CONCLUSION: These findings suggest that a simple blood-based signature not only provides estimates of NAB but also predicts cognitive decline and disease progression, identifying individuals at risk of progressing toward AD at the prodromal and preclinical stages. © 2016 American Academy of Neurology |
http://www.ibas.org.au/what-we-do/publications/3872853
Interstitial lung disease (ILD) is a chronic lung condition that causes stiff lungs and restricts sufferers from taking a deep breath. Exercise in a gym, or swimming, walking or riding a bike, can help...
SHIFT WORK AND BREASTFEEDING PROJECT
Researchers at Austin Health are looking for volunteers to participate in a study exploring the impact shift work has on breast milk composition. Participants will be compensated with a $100 gift voucher.
HEALTHY MALES AND FEMALES WANTED FOR SLEEP STUDY
Interested to participate in a study investigating the effect of fatigue on driving performance?
A/PROF MARK HOWARD AWARDED MAJOR COMPETITIVE MRFF GRANT
IBAS leads project to revolutionize Home Ventilation with $1.2 million grant for Assoc. Prof Mark Howard's research titled "Synchronise non-invasive ventilation at home".
PROF ANNE HOLLAND RECEIVES PRESTIGIOUS RESEARCH AWARD
Prof Anne Holland receives prestigious award for Excellent in Research Engagement and Impact from Monash University.
WORLD SLEEP DAY ON 17TH MARCH 2023
The benefits of quality sleep and to acknowledge the issue of sleep problems and their medical, educational, and social aspects as well as the prevention and management of sleep disorders, is promoted on World Sleep Day on the 17th March 2023.
A/PROF MARK HOWARD IS LISTED IN 'THE AUSTRALIAN'
The Australian's Research magazine names the top researcher and top research institution in each field of research, based on the number of citations for papers published in the top 20 journals in each field over the past five years.
© 2024 Institute for Breathing and Sleep. All Rights Reserved. ABN 39 093 685 879
Powered by Helmut Design | Manage
